Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials
Our meta-analysis demonstrates that incorporation of BV into frontline therapy for classical HL provides significant PFS benefits and improved end-of-treatment metabolic responses, with manageable toxicity. These findings support BV-based regimens as a promising frontline therapeutic strategy in classical HL, though extended follow-up is required to evaluate long-term survival outcomes.
Authors
- Jing Xie (ORCID: https://orcid.org/0000-0002-5065-7911)
- Rui Zhang (ORCID: https://orcid.org/0000-0001-5691-8329)
- Shurong Liu (ORCID: https://orcid.org/0000-0002-5456-8828)
- Li Wang (ORCID: https://orcid.org/0000-0003-3722-5986)
- Yue Yang (ORCID: https://orcid.org/0000-0002-8270-9464)
Institutions
- Union Hospital (HK)
- PLA Rocket Force University of Engineering (CN)
- Beijing Emergency Medical Center (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-21
- DOI
- https://doi.org/10.3389/fonc.2025.1636923
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47